Inventiva S.A. (NASDAQ:IVA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Inventiva S.A. (NASDAQ:IVA) has received a consensus recommendation of “Moderate Buy” from the six analysts that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $12.00.

A number of research firms have recently commented on IVA. Guggenheim lowered their target price on Inventiva from $12.00 to $9.00 and set a “buy” rating for the company in a research report on Friday. HC Wainwright reissued a “buy” rating and issued a $13.00 price objective on shares of Inventiva in a research note on Friday, March 28th. Finally, TD Cowen began coverage on Inventiva in a research report on Friday, February 21st. They issued a “buy” rating and a $10.00 price target for the company.

Inventiva Trading Up 6.1 %

Shares of Inventiva stock traded up $0.19 during trading on Friday, reaching $3.21. 28,588 shares of the stock traded hands, compared to its average volume of 62,422. Inventiva has a 52-week low of $1.53 and a 52-week high of $3.98. The business has a fifty day simple moving average of $2.76 and a two-hundred day simple moving average of $2.50.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.